Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Enters 2009 Focused On 2010 Patent Expirations

This article was originally published in PharmAsia News

Executive Summary

Takeda Pharmaceuticals enters 2009 with its focus on 2010 when its pipeline of best-selling drugs begins losing patent protection. The company's actions, as expressed by its President Yasuchika Hasegawa recently, is focused on taking advantage of recent acquisitions to reshape that pipeline with a concentration on oncology drugs. Recent purchases of major foreign drug makers have been aimed at Takeda's entry into a sector of the drug market it believes holds potential. To make the move, its management style changed from conservative to an acquisition spree that has made it one of the big three in cancer drugs. (Click here for more - a subscription may be required)

You may also be interested in...



Novartis CEO Backs Malaria Drug Against COVID-19

A coronavirus vaccine is some way off and until then, Vas Narasimhan, head of Novartis, is thinking that of the drugs being repurposed to treat COVID-19, hydroxychloroquine looks best places to provide the quickest benefit.

COVID-19 May Delay WHO’s Prequalification Of Devices, IVDs

Work and movement-related restrictions are affecting the ability of companies to provide a timely response to questions relating to their prequalification dossiers.

COVID-19 May Delay WHO’s Prequalification Of Drugs, Devices, IVDs

Work and movement-related restrictions are affecting the ability of companies to provide a timely response to questions relating to their prequalification dossiers.

UsernamePublicRestriction

Register

SC069828

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel